Skip to content
Research Article Open access CC BY 3.0

Improve Markers of Oxidative Stress and Coagulation Parameters in Response to Atorvastatin Therapy

Bassim I. Mohammad, Najah R. Hadi, Haider M. Jawad, Dina A. Jamil, Hayder A. Al-Aubaidy

Journal of Pharmaceutical Research International · pp. 1242–1252 · Published 15 May 2014

10.9734/BJPR/2014/10140

Abstract

Aims: This study was undertaken to investigate the antioxidant effects of atorvastatin in treating cases of atherosclerosis associated with hyperlipidemia. Methodology: Forty local domestic rabbits were assigned to five groups (eight rabbits in each group): After two weeks acclimatization period, a group of 8 rabbits (Group I) were used as the baseline values of the study parameters. Another 8 rabbits were selected and maintained on standard chow diet (4% fat, 18% protein, 60% carbohydrate, and 4% fibers) throughout the experiment (12 weeks) and served as a normal diet control (Group II). The rest 24 rabbits were fed on an atherogenic diet for 8 weeks to induce atherogenesis. At the end of 8th week, a group of 8 atherogenic rabbits (Group III) were separated and sacrificed and served as an atherogenic-baseline group. The remaining 16 atherogenic rabbits were randomly allocated into two groups; first group received atherogenic diet only for the next four weeks and served as an atherogenic control (Group IV). The other group received atorvastatin (Group V). Results: Blood samples were collected for serum lipids, coagulation parameters and oxidation parameters. Results showed a significant improvement in the coagulation parameters and oxidation parameters in the atorvastatin treated group compared to the atherogenic control group (P= .01). Conclusion: This study illustrated the beneficial anti-oxidant effects of atorvastatin in treating atherosclerosis associated with hyperlipidemia.

Atorvastatin coagulation oxidative stress antioxidants atherosclerosis

References (49)

  1. 1 [30] Microsomal lipid peroxidation [DOI]
  2. 2 Assessment of current diagnostic criteria for Guillain-Barr� syndrome [DOI]
  3. 3 The estimation of red cell superoxide dismutase activity.
  4. 4 Peripheral neuropathies and anti-glycolipid antibodies [DOI]
  5. 5 Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in guillain-barre syndrome [DOI]
  6. 6 Guillain-Barré syndrome [DOI]
  7. 7 Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia [DOI]
  8. 8 HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis [DOI]
  9. 9 Antiphospholipid antibodies and thrombosis [DOI]
  10. 10 Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
  11. 11 Lipid peroxides induce expression of catalase in cultured vascular cells [DOI]
  12. 12 Antioxidant effect of aqueous extract of the bark of Ficus bengalensis in hypercholesterolaemic rabbits [DOI]
  13. 13 Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group.
  14. 14 HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins [DOI]
  15. 15 Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload [DOI]
  16. 16 Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia [DOI]
  17. 17 CNS dysfunction in the antiphospholipid syndrome [DOI]
  18. 18 Assessing the Usefulness of Anticardiolipin Antibody Assays [DOI]
  19. 19 8-Hydroxy-2-deoxy-guanosine identifies oxidative DNA damage in a rural prediabetes cohort [DOI]
  20. 20 The effect of ethanol extract of Hypericum lysimachioides on lipid profile in hypercholesterolemic rabbits and its in vitro antioxidant activity [DOI]
  21. 21 Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection [DOI]
  22. 22 Relationship between mean platelet volume and low-grade systemic coagulation with vitamin D deficiency in primary ovarian insufficiency [DOI]
  23. 23 Oxidative DNA damage: antioxidant response in postprandial hyperglycaemia in type 2 diabetes mellitus [DOI]
  24. 24 Lethal damage to endothelial cells by oxidized low density lipoprotein: role of selenoperoxidases in cytoprotection against lipid hydroperoxide- and iron-mediated reactions. [DOI]
  25. 25 Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia [DOI]
  26. 26 Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies [DOI]
  27. 27 Practical Haematology [DOI]
  28. 28 Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia [DOI]
  29. 29 Effects of Statins on Oxidative Stress [DOI]
  30. 30 Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA [DOI]
  31. 31 HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide [DOI]
  32. 32 Increased Fibrinogen Levels and Acquired Hypofibrinolysis in Young Adults With Ischemic Stroke [DOI]
  33. 33 Antioxidant activity of ezetimibe in hypercholesterolemic rats [DOI]
  34. 34 Hyperuricemia Is a Mediator of Endothelial Dysfunction and Inflammation in Renal Allograft Recipients [DOI]
  35. 35 Antiatherosclerotic potential of aliskiren: its antioxidant and anti-inflammatory effects in rabbits: a randomized controlled trial [DOI]
  36. 36 The antiphospholipid (Hughes') syndrome: changing the face of neurology [DOI]
  37. 37 Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome [DOI]
  38. 38 Effects of Atorvastatin on Red-blood Cell Na+/Li+ Countertransport in Hyperlipidemic Patients With and Without Hypertension [DOI]
  39. 39 Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause?
  40. 40 ANTIPHOSPHOLIPID ANTIBODIES [DOI]
  41. 41 Effect of cholesterol-rich diets with and without added vitamins E and C on the severity of atherosclerosis in rabbits [DOI]
  42. 42 Autoantibodies to Phospholipids and Brain Extract in Patients with the Guillain-Barre Syndrome: Cross-Reactive or Pathogenic? [DOI]
  43. 43 Antithrombotic actions of statins.
  44. 44 Anti‐GM1, anti‐central myelin proteins, and anti‐cardiolipin autoantibodies during plasma‐exchange in Guillain‐Barré syndrome (GBS) [DOI]
  45. 45 HYPERURICEMIA IS A MEDIATOR OF ENDOTHELIAL DYSFUNCTION AND INFLAMMATION IN RENAL ALLOGRAFT RECIPIENTS [DOI]
  46. 46 Relationship between Prothrombin Activation Fragment F1 +2 and Serum Cholesterol [DOI]
  47. 47 Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia [DOI]
  48. 48 Statins and fibrinogen [DOI]
  49. 49 Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?

Cited by 2

Cardiovascular Effects of Copper Deficiency on Activity of Superoxide Dismutase in Diabetic Nephropathy

M. Al-Bayati, D. Jamil, Hayder A. Al-Aubaidy · North American Journal of Medicine and Science · 2015

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

40

Page views

0

PDF downloads

9

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.